Special Issue Article
Viral Factors Associated with Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection
Yoshio Aizawa* and Hiroshi Abe
Division of Gastroenterology and Hepatology, Jikei University Katsushika Medical Center, Japan
- *Corresponding Author:
- Yoshio Aizawa
Division of Gastroenterology and Hepatology
Jikei University Katsushika Medical Center
6-41-2 Aoto, Katsushikaku, Tokyo 125-8506, Japan
Received Date: March 16, 2012; Accepted Date: March 22, 2012; Published Date: March 24, 2012
Citation: Aizawa Y, Abe H (2012) Viral Factors Associated With Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection. J Antivir Antiretrovir S3. doi: 10.4172/jaa.S3-003
Copyright: © 2012 Aizawa Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A first-generation protease inhibitor (PI) against HCV non-structural 3/4A serine protease was approved worldwide at the end of 2011. We are now facing a revolutionary change in therapeutic strategies for chronic HCV infection, from interferon (IFN)-based therapies to direct-acting antivirals (DAAs). The efficacy of antiviral therapy varies with HCV genotype. The most intractable and most common HCV worldwide is HCV genotype 1 (G1). Viral and host factors participating in the virological outcome of IFN-based therapy have been extensively examined. However, in the era of DAAs, the significance of these factors will gradually decrease. Instead, viral factors related to resistance against DAAs are becoming the main focus. In this review, the viral factors participating in the response to IFN-based therapies are summarized, and the issue of viral resistance to DAAs is discussed.